Vanda Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VANDA PHARMS INC, and what generic alternatives to VANDA PHARMS INC drugs are available?
VANDA PHARMS INC has three approved drugs.
There are thirty-nine US patents protecting VANDA PHARMS INC drugs.
There are two hundred and forty-three patent family members on VANDA PHARMS INC drugs in twenty-four countries.
Summary for Vanda Pharms Inc
International Patents: | 243 |
US Patents: | 39 |
Tradenames: | 3 |
Ingredients: | 2 |
NDAs: | 3 |
Drugs and US Patents for Vanda Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 9,730,910 | ⤷ Sign Up | ⤷ Sign Up | |||
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 11,786,502 | ⤷ Sign Up | ⤷ Sign Up | |||
Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | 11,285,129 | ⤷ Sign Up | ⤷ Sign Up | ||||
Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | 11,826,339 | ⤷ Sign Up | ⤷ Sign Up | ||||
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 10,945,988 | ⤷ Sign Up | ⤷ Sign Up | |||
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 10,376,487 | ⤷ Sign Up | ⤷ Sign Up | |||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-006 | May 6, 2009 | RX | Yes | No | 8,586,610 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Vanda Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | 5,856,529 | ⤷ Sign Up |
Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | 5,856,529 | ⤷ Sign Up |
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-006 | May 6, 2009 | RE39198 | ⤷ Sign Up |
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | RE39198 | ⤷ Sign Up |
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-004 | May 6, 2009 | RE39198 | ⤷ Sign Up |
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-003 | May 6, 2009 | RE39198 | ⤷ Sign Up |
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | RE39198 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VANDA PHARMS INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2018-01-31 |
➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2018-01-31 |
➤ Subscribe | Tablets | 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, & 12 mg | ➤ Subscribe | 2013-05-06 |
International Patents for Vanda Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Russian Federation | 2748386 | ⤷ Sign Up |
Japan | 2020079248 | ⤷ Sign Up |
European Patent Office | 2806863 | ⤷ Sign Up |
Spain | 2688476 | ⤷ Sign Up |
New Zealand | 777266 | ⤷ Sign Up |
Denmark | 2806863 | ⤷ Sign Up |
Japan | 5692872 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.